COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | $524,193,713 | $612,492,780 | $271,242,688 | $250,361,498 |
| - Cash | $57,038,000 | $52,301,000 | $45,928,000 | $37,362,000 |
| + Debt | $49,957,000 | $34,063,000 | $18,201,000 | $9,413,000 |
| Enterprise Value | $517,112,713 | $594,254,780 | $243,515,688 | $222,412,498 |
| Revenue | $1,011,390,000 | $964,989,000 | $827,697,000 | $755,414,000 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Gross Profit | $213,281,000 | $188,306,000 | $168,718,000 | $151,448,000 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| EBITDA | $64,855,000 | $53,742,000 | $50,192,000 | $48,210,000 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |
| Net Income | $30,978,000 | $24,454,000 | $23,797,000 | $23,155,000 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS Diluted | 390.86 | 308.61 | 600.95 | 584.74 |
| % Growth | 26.7% | -48.6% | 2.8% | – |
| Operating Cash Flow | $52,467,000 | $55,175,000 | $54,434,000 | $32,194,000 |
| Capital Expenditures | -$53,326,000 | -$55,810,000 | -$46,636,000 | -$43,497,000 |
| Free Cash Flow | -$859,000 | -$635,000 | $7,798,000 | -$11,303,000 |